Blood Cancer Drugs Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact – both negative and positive – of COVID-19 on the blood cancer drugs industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. This includes revised market numbers according to the effects of the coronavirus and the expected blood cancer drugs market growth numbers 2021-2030.
View Complete Report:
The Blood Cancer Drugs Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global blood cancer drugs market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030. The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Blood Cancer Drugs Global Market Report 2021 covers blood cancer drugs market drivers, blood cancer drugs market trends, blood cancer drugs market growth rate, blood cancer drugs market major players, player-adopted strategies in the market, and blood cancer drugs market size.
The global blood cancer drugs market is expected to grow from $20.66 billion in 2020 to $21.6 billion in 2021 at a compound annual growth rate (CAGR) of 4.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $28.7 billion in 2025 at a CAGR of 7.4%.
Request For The Sample Now:
The report covers the blood cancer drugs market segments-
1) By Blood Cancer Type: Leukemia, Lymphoma, Myeloma
2) By Drugs: Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/